News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-290


7/7/2014 10:11:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEIJING--(BUSINESS WIRE)--BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced that it has dosed the first patient in a Phase 1 study of BGB-290 for the treatment of cancer. BGB-290 is an investigational, oral, selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme family which is involved in a number of cellular processes, including DNA repair and programmed cell death.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES